Table 1:
Baseline characteristics of the study population
| Overall cohort (N=48) |
Validation cohort (N=34) |
Reproducibility cohort (N=14) |
|
|---|---|---|---|
| Demographics | |||
| Age | 63 (52-72) | 63 (54-73) | 63 (54-70) |
| Male sex | 23 (47.9%) | 17 (50%) | 6 (42.9%) |
| White race | 39 (81.3%) | 28 (82.4%) | 11 (78.6%) |
| Non-Hispanic | 46 (95.8%) | 32 (94.1%) | 14 (100%) |
| BMI | 30.6 (27.6-33.6) | 31.1 (27.8-34.1) | 28.7 (26.9-32.6) |
| Clinical characteristics | |||
| History of known CAD | 13 (27.1%) | 11 (32.4%) | 2 (14.3%) |
| Family history of known CAD | 17 (35.4%) | 12 (35.3%) | 5 (35.7%) |
| Hypertension | 40 (83.3%) | 30 (88.2%) | 10 (71.4%) |
| Dyslipidemia | 35 (72.9%) | 25 (73.5%) | 10 (71.4%) |
| Diabetes mellitus | 12 (25%) | 9 (26.5%) | 3 (21.4%) |
| Current smoker | 6 (12.5%) | 2 (5.9%) | 4 (28.6%) |
| Previous MI or acute coronary syndrome | 9 (18.8%) | 7 (20.6%) | 2 (14.3%) |
| Revascularization history (PCI/CABG) | 9 (18.8%) | 7 (20.6%) | 2 (14.3%) |
| History of stroke or transient ischemic attack | 2 (4.2%) | 1 (2.9%) | 1 (7.1%) |
| Peripheral artery disease | 7 (14.6%) | 5 (14.7%) | 2 (14.3%) |
| Medications | |||
| Beta-blockers | 25 (52.1%) | 20 (58.8%) | 5 (35.7%) |
| ACE inhibitors | 16 (33.3%) | 12 (35.3%) | 4 (28.6%) |
| ARB | 9 (18.8%) | 7 (20.6%) | 2 (14.3%) |
| Statins | 31 (64.6%) | 23 (67.6%) | 8 (57.1%) |
| Nitroglycerin | 6 (12.5%) | 4 (11.8%) | 2 (14.3%) |
| Antiplatelet therapy | 17 (35.4%) | 11 (32.4%) | 6 (42.9%) |
| Anticoagulation | 7 (14.6%) | 7 (20.6%) | 0 (0%) |
| Diuretics | 17 (35.4%) | 14 (41.2%) | 3 (21.4%) |
| Insulin | 5 (10.4%) | 3 (8.8%) | 2 (14.3%) |
Values are presented as median and interquartile ranges (IQR) or n (%).
ACE=angiotensin-conversing enzyme; ARB=angiotensin-II receptor blocker; BMI = body mass index; CAD= coronary artery disease; CABG=coronary artery bypass grafting; PCI = percutaneous coronary intervention.